No­var­tis rides with Bi­cy­cle for new pact on tar­get­ed ra­dio­ther­a­pies

No­var­tis has inked a three-year deal with Bi­cy­cle Ther­a­peu­tics to de­vel­op new tar­get­ed ra­dio­ther­a­pies for can­cer.

No­var­tis will pay Bi­cy­cle $50 mil­lion up­front, with down­stream mile­stones adding up to a po­ten­tial $1.7 bil­lion. In ex­change, Bi­cy­cle will use its virus-based plat­form to dis­cov­er new bi­cyclic pep­tides, which it calls bi­cy­cles, that would be used for ra­dio­ther­a­pies. Those bi­cy­cles would act as a hom­ing bea­con for ra­dioac­tive iso­topes, de­liv­er­ing them to can­cer cells to kill the cells while lim­it­ing ra­di­a­tion to healthy tis­sue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER